Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 10/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733475 | 0.84 | DPP4 (0.35) | POLBKDM4EALDH1A1DPP4DPP7 | |
| SCHEMBL12733482 | 0.84 | DPP4 (0.35) | POLBKDM4EALDH1A1DPP4DPP7 | |
| SCHEMBL13121551 | 0.83 | POLB (0.43) | POLBKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL12733491 | 0.83 | POLB (0.43) | POLBKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL13121028 | 0.76 | PEPD (0.32) | — | |
| SCHEMBL2501850 | 0.75 | PEPD (0.34) | — | |
| SCHEMBL15745572 | 0.74 | PEPD (0.33) | ALDH1A1DPP4DPP8 | |
| SCHEMBL12733485 | 0.73 | SSTR4 (0.48) | — | |
| SCHEMBL10120780 | 0.73 | DPP4 (0.33) | DPP4DPP7DPP8 | |
| SCHEMBL12733414 | 0.73 | POLB (0.58) | POLBKDM4EALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440626-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO. KG (DE) | 2011-04-28 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234205-A1 | Antineoplastic peptides | BCL2A1, ETF1, BAK1 | POLB 384/4885KDM4E 2238/4885ALDH1A1 4381/4885 |
| US-20110098235-A1 | ANTINEOPLASTIC PEPTIDES | BCL2A1, CSTB, BAK1 | POLB 308/4885KDM4E 3028/4885ALDH1A1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.